Meeting
2017 Genitourinary Cancers Symposium
Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.
Authors
Nicholas J. Vogelzang
Comprehensive Cancer Centers of Nevada, Las Vegas, NV
Nicholas J. Vogelzang , Sumanta K. Pal , Sameer Ghate , Nanxin Li , Elyse Swallow , Miranda Peeples , Miriam Zichlin , Mark Meiselbach , Jose Ricardo Perez , Neeraj Agarwal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 475)
DOI
10.1200/JCO.2017.35.6_suppl.475
Abstract #
475
Poster Bd #
E14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman
Poster
2015 Genitourinary Cancers Symposium
Sunitinib and pazopanib treatment patterns and cost outcomes in Medicare supplemental-covered patients with renal cell carcinoma.
First Author: James Harnett
Poster
2024 ASCO Genitourinary Cancers Symposium
A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Outcomes at 36 months post treatment initiation.
First Author: Paul D. Nathan
Poster
2023 ASCO Genitourinary Cancers Symposium
CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy.
First Author: Paul D. Nathan